<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472900</url>
  </required_header>
  <id_info>
    <org_study_id>ERYAG-AC01</org_study_id>
    <nct_id>NCT01472900</nct_id>
  </id_info>
  <brief_title>2940nm Er:YAG Laser Versus Benzoyl Peroxide Gel for the Treatment of Inflammatory Acne</brief_title>
  <official_title>A Randomized Split-Face Controlled Trial Comparing Efficacy of 2940 Nanometer Er:YAG Laser to 2.5% BP Gel for the Treatment of Inflammatory Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <brief_summary>
    <textblock>
      Acne is one of the most common conditions that patients seek for help in dermatological
      clinic. Nowadays, conventional treatment including topical agents(retinoids, antibiotics
      ,antiseptics and keratolytic agents) and systemic agents( antibiotics and retinoids) give a
      satisfying result but not to every patient. Some patients are not well respond to
      conventional therapy while some patients are unable to tolerate side effects of the
      treatments. Therefore, interventions to reduce acne are vigorously experimented . Lights and
      lasers including intense pulsed light, pulsed dye laser with or without photosensitizer and
      infrared lasers have been found to be useful in treating active inflammatory acne.
      Although,pain ,downtime and poor response of comedonal acne are limitations of those lights
      and lasers therapy. 2940 nm Erbium:YAG laser which has both resurfacing and photothermal
      effects is our laser of interest to seek for its efficacy in the treatment of inflammatory
      acne.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage change from baseline of inflammatory acne lesion count at 6 week after 1st 2940nm Er:YAG laser treatment</measure>
    <time_frame>6 week</time_frame>
    <description>% change from baseline = (NV- NB)/NB x 100% NV = number of lesion at each visit NB = number of lesion at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>week0,2,4</time_frame>
    <description>Safety profile of 2940nm Er:YAG laser for the treatment of inflammatory acne including;
Visual analogue scale of pain score
Adverse events(AEs) include types of AEs(erythema, pain/burning sensation, dryness/excessive scaling, pigmentary change), timing, intenstity, outcome and action taking regarding to study procedure particular subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Photographic clinical improvement</measure>
    <time_frame>week 2,4,6 and 10</time_frame>
    <description>Photographic clinical improvement of acne, acne scar, erythema, hyperpigmentation and overall improvement by blinded dermatologists using quartile grading system comparing baseline and each clinical visit (week 2,4,6 and 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>week 6</time_frame>
    <description>Self evaluation of patient satisfaction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Er:YAG laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BP gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)</intervention_name>
    <description>2 passes of 2940nm Er:YAG laser</description>
    <arm_group_label>Er:YAG laser</arm_group_label>
    <other_name>DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzoyl Peroxide gel</intervention_name>
    <description>2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face</description>
    <arm_group_label>BP gel</arm_group_label>
    <other_name>2.5% benzoyl peroxide gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 year-old to 45 year-old

          -  Mild to moderate severity of acne vulgaris with at least 5 active inflammatory acne
             lesions on each side of the face and less than 25% difference in lesion count between
             each side of face

          -  Fitzpatrick skin phototype I-IV

        Exclusion Criteria:

          -  History or clinical presentation of hypertrophic scar or keloid

          -  Photoaggravated skin diseases i.e. systemic lupus erythematosus, polymorphous light
             eruption, solar urticaria

          -  Oral isotretinoin taken within the last 6 months prior to enrollment

          -  Topical retinoid within 4 weeks prior to enrollment

          -  Systemic acne therapies (oral antibiotics) within 4 week prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/12833004</url>
    <description>Management of acne: a report from a Global Alliance to Improve Outcomes in Acne</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/17007539</url>
    <description>Persistent acne in women : implications for the patient and for therapy</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/10233319</url>
    <description>The quality of life in acne: a comparison with general medical conditions using generic questionnaires</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19376456</url>
    <description>New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/18561586</url>
    <description>Prevalence and severity of facial and truncal acne in a referral cohort</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19439880</url>
    <description>Profile of acne vulgaris--a hospital-based study from South India</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/17276540</url>
    <description>Guidelines of care for acne vulgaris management</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <last_update_submitted>June 17, 2012</last_update_submitted>
  <last_update_submitted_qc>June 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Nattaporn Rojarayanont, M.D.</investigator_full_name>
    <investigator_title>Faculty of Medicine, Department of Medicine, Dermatological unit</investigator_title>
  </responsible_party>
  <keyword>acne vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

